HeartBeam (BEAT) awards 41,380-share stock option grant to major holder

Rhea-AI Filing Summary

HeartBeam, Inc. reported that major shareholder Mark E. Strome received a grant of stock options to acquire 41,380 shares of common stock at an exercise price of $1.43 per share. Half of these options vest on March 31, 2026 and the remaining half on June 30, 2026, with an expiration date of January 1, 2036. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent compensation rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider STROME MARK E

Role 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Common Stock (right to buy)	41,380	$0.00	--

Holdings After Transaction: Common Stock (right to buy) — 41,380 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STROME MARK E

(Last) (First) (Middle)

2118 WALSH AVENUE, SUITE 210

(Street)

SANTA CLARA CALIFORNIA 95050

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HeartBeam, Inc. [ BEAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock (right to buy)	$1.43	02/09/2026		A		41,380		(1)	01/01/2036	Common Stock	41,380	$0	41,380	D

Explanation of Responses:

1. Granted options on February 9, 2026 (the "Special Option"), one half of the total number of shares of common stock (the "Shares") subject to the Special Option shall vest on March 31, 2026, the three-month anniversary of the vesting commencement date beginning January 1, 2026, and the remaining Shares of common stock shall vest on June 30, 2026, the six-month anniversary of the vesting commencement date. These options have been issued from the Company's 2022 Equity Incentive Plan.

	/s/ Mark E. Strome	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did HeartBeam (BEAT) report for Mark E. Strome?

HeartBeam reported a grant of stock options to major shareholder Mark E. Strome for 41,380 shares. These options give him the right to buy common stock at a fixed exercise price as part of compensation, not an open-market trade.

How many HeartBeam (BEAT) shares are covered by the new option grant?

The new option grant covers 41,380 shares of HeartBeam common stock. This figure reflects the total number of underlying shares subject to the options awarded to Mark E. Strome in this Form 4 filing.

What is the exercise price of Mark E. Strome’s HeartBeam (BEAT) stock options?

The options granted to Mark E. Strome have an exercise price of $1.43 per share. This means he can purchase HeartBeam common stock at that price once the options vest, regardless of future market price.

When do Mark E. Strome’s HeartBeam (BEAT) options vest?

Half of the options vest on March 31, 2026 and the remaining half on June 30, 2026. The vesting schedule ties to a commencement date of January 1, 2026, as described in the filing footnote.

When do the newly granted HeartBeam (BEAT) options to Mark E. Strome expire?

The granted stock options expire on January 1, 2036. After that date, any unexercised options will lapse, and Mark E. Strome would no longer have the right to purchase HeartBeam shares under this grant.

Under which plan were the HeartBeam (BEAT) options to Mark E. Strome issued?

These stock options were issued under HeartBeam’s 2022 Equity Incentive Plan. Such plans are commonly used to grant equity-based compensation to executives, directors, or significant shareholders to align interests with the company’s long-term performance.